Enovis Corp (ENOV)

Currency in USD
26.06
-0.12(-0.46%)
Closed·
26.060.00(0.00%)
·
Advertisement
ENOV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
25.5026.41
52 wk Range
19.1434.28
Key Statistics
Prev. Close
26.18
Open
26.19
Day's Range
25.5-26.41
52 wk Range
19.14-34.28
Volume
611K
Average Volume (3m)
1.17M
1-Year Change
-17.112%
Book Value / Share
25.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENOV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.83
Upside
+56.69%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Enovis Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

12 Buy
1 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.83
(+56.69% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy45.00+72.68%50.00Maintain17/08/2026
BMO Capital
Buy30.00+15.12%29.00Maintain07/08/2026
Wells Fargo
Buy39.00+49.65%40.00Maintain07/08/2026
UBS
Buy51.00+95.70%50.00Maintain28/07/2026
BMO Capital
Buy---New Coverage08/07/2026

Enovis Corp Earnings Call Summary for Q2/2026

  • Enovis posted Q2 2026 adjusted EPS of $0.90, beating consensus of $0.85 by 5.88%, while revenue of $582.78M matched forecasts.
  • Shares fell 6.69% to $28.16 despite earnings beat as company reaffirmed full-year guidance without raising outlook amid cost pressures.
  • Gross margin expanded to 62% and adjusted EBITDA margin reached 17.9%; leverage improved to 3.1x with positive first-half free cash flow.
  • Management expects Q3 softness due to Western Europe weakness and Middle East disruption, with Q4 improvement from new product launches.
  • CEO highlighted ARVIS robotic system's full U.S. launch and stated current high-teens EBITDA margins insufficient for company's ambitions.
Last Updated: 06/08/2026, 14:40
Read Full Transcript

Earnings

Latest Release
06/08/2026
EPS / Forecast
0.90 / 0.85
Revenue / Forecast
582.78M / 582.74M
EPS Revisions
Last 90 days

Enovis (ENOV) Income Statement & Profits

Compare ENOV to Peers and Sector

Metrics to compare
ENOV
Peers
Sector
Relationship
P/E Ratio
−1.4x−2.3x−0.4x
PEG Ratio
0.04−0.240.00
Price/Book
1.0x3.8x2.6x
Price / LTM Sales
0.7x1.4x3.1x
Upside (Analyst Target)
53.5%18.9%48.9%
Fair Value Upside
Unlock9.5%6.2%Unlock

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
37.18M64.47%968.87M
Other Institutional Investors
33.82M35.53%881.29M
Public Companies & Retail Investors
0.000.00%0.00
Total
71M100.00%1.85B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.17.85%10,295,666268,305
American Century Investment Management Inc10.59%6,106,561159,137

People Also Watch

18.80
UPBD
+1.40%
16.57
SBH
+2.09%
96.66
AX
+0.73%
8.43
CERT
-3.44%
16.74
IART
+0.90%

FAQ

What Is the Enovis (NYSE: ENOV) Share Price Today?

The Enovis stock price today is 26.06 USD.

What Stock Exchange Does Enovis (ENOV) Trade On?

Enovis is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Enovis?

The stock symbol (also called a 'ticker') for Enovis is "ENOV."

What Is the Current Enovis Market Capitalisation?

As of today, Enovis (NYSE: ENOV) market cap is 1.51B USD.

What Is Enovis's (ENOV) Earnings Per Share (TTM)?

The Enovis EPS is currently -19.19 (Trailing Twelve Months).

When Is the Next Enovis Earnings Date?

Enovis's next earnings report will be released on 11/11/2026.

Is ENOV a Buy or Sell From a Technical Analyst Perspective?

Based on today's Enovis moving averages and other technical indicators, the daily buy/sell signal for ENOV stock is Neutral.

How Many Times Has Enovis Stock Split?

Enovis has split 1 times. (See the ENOV stock split history page for full effective split date and price information.)

How Many Employees Does Enovis Have?

Enovis has 7802 employees, based on their latest Companies House report.

What is the current trading status of Enovis (NYSE: ENOV)?

As of 23/08/2026, Enovis (ENOV) is trading at a share price of 26.06 USD, with a previous close of 26.18 USD. The stock has fluctuated within a day range of 25.50 USD to 26.41 USD, while its 52-week range spans from 19.14 USD to 34.28 USD.

What Is Enovis (ENOV) Price Target According to Analysts?

The average 12-month price target for Enovis is 40.83 USD, with a high estimate of 55 USD and a low estimate of 28 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +56.69% Upside potential.

What Is the ENOV Premarket Price?

ENOV's last pre-market stock price is 25.82 USD. The pre-market share volume is 10.00, and the stock has decreased by -0.36, or -1.38%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.